Results 131 to 140 of about 32,431 (267)

Gut microbiota as a novel therapeutic target for eating disorders and obesity

British Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė, Victor Mathis, Emmanuel Darcq, Aurelijus Burokas, Elena Martín‐García, Rafael Maldonado   +5 more
wiley   +1 more source

The role of macrophage migration inhibitory factor (MIF) in the pathogenesis and progression of cardiovascular disease

British Journal of Pharmacology, EarlyView.
Abstract Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury.
Shreya Mahabhashyam, James Harris, Jürgen Bernhagen, Antony Vinh, Katrina M. Mirabito Colafella   +4 more
wiley   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

Invasive sellar extraventricular neurocytoma: illustrative case. [PDF]

J Neurosurg Case Lessons
Gilbert OE, Dillard JA, Franklin D, Kargi AY, Vuncannon J, Higgins DMO.   +5 more
europepmc   +1 more source

The effect of prostacyclin on pituitary hormone release [letter] [PDF]

British Journal of Clinical Pharmacology, 1980
B Allolio, GA Fitzgerald, FX Hipp, V Hossmann, R Mies, W Winkelmann   +5 more
openaire   +1 more source

MEN1 Deficiency Drives Lung Cancer Progression via Activation of MMP10‐Mediated Angiogenesis

Cancer Science, EarlyView.
MEN1 deficiency promotes JunD‐mediated upregulation of MMP10 expression, which cleaves pro‐HB‐EGF and activates endothelial EGFR. This triggers the PI3K/Akt and MEK/ERK signaling pathways, thereby driving angiogenesis and tumor progression. MMP10 inhibitor treatment blocks this cleavage, suppresses EGFR signaling, and thereby delays malignant ...
Chengyu Wei, Xiangyu Liu, Shimin Hu, Xiaodie Shen, Yingli Liu, Xinxin Qin, Ye Zhou, Jianqi Zheng, Bingke Tian, Jingfang Hong, Yongxia Song, Di Wang, Linlin Peng, Jinxia Ding, Fang Wang, Hui Zhang, Shihao Zhang, Huan Qiu   +17 more
wiley   +1 more source

Possible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone. [PDF]

Int J Mol Sci
Otsuka Y, Soejima Y, Nakano Y, Suyama A, Takase R, Oguni K, Masuda Y, Omura D, Sakurada Y, Matsuda Y, Hasegawa T, Honda H, Tokumasu K, Ueda K, Otsuka F.   +14 more
europepmc   +1 more source

The Spectrum of Congenital Hypogonadotropic Hypogonadism: A 30‐Year Experience at a Tertiary Paediatric Centre

Clinical Endocrinology, EarlyView.
ABSTRACT Congenital hypogonadotropic hypogonadism (CHH) is a rare group of disorders of gonadotropin deficiency, either isolated or as a part of multiple pituitary hormone deficiencies (MPHD). We aimed to describe the spectrum of presentation, diagnosis, and management practices of CHH spanning 30 years at an Australian tertiary paediatric centre. This
Minha Kook, Richard G. McGee, Geoffrey Ambler, Yoon Hi Cho   +3 more
wiley   +1 more source

The relationships between diabetic male infertility, diabetic cognitive impairment, and the neuroendocrine-immune network: A review. [PDF]

Medicine (Baltimore)
Cao SM, Guo L, Han XY, Wang T, Wang W, Wu ZM, Fu XH.   +6 more
europepmc   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

Clinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams, Bonnie Grant, Richard Quinton, Channa N. Jayasena   +3 more
wiley   +1 more source